CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network

CAR T-Cells for CNS Lymphoma: Driving into New Terrain?

(2021) Philipp Karschnia et al.   Cancers

Emerging Landscape of Immunotherapy for Primary Central Nervous System Lymphoma

(2021) Marion Alcantara et al.   Cancers

Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure

(2020) Jordan Gauthier et al.   BLOOD

Management and outcome of primary CNS lymphoma in the modern era

(2020) Caroline Houillier et al.   NEUROLOGY

CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain

(2020) Tongjuan Li et al.   Frontiers in Oncology

Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies

(2020) Kevin R. Parker et al.   CELL

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

(2020) Jeremy S Abramson et al.   LANCET

CAR T-cell associated neurotoxicity: Mechanisms, clinicopathologic correlates, and future directions

(2019) Bradley D Hunter et al.   JNCI-Journal of the National Cancer Institute

Tisagenlecleucel CAR-T Cell Therapy in Secondary CNS Lymphoma

(2019) Matthew J. Frigault et al.   BLOOD

CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma

(2019) Tanya Siddiqi et al.   BLOOD

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

(2018) Frederick L Locke et al.   LANCET ONCOLOGY

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma

(2017) Jeremy S. Abramson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma

(2016) M. Ruella et al.   CLINICAL CANCER RESEARCH

Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses

(2015) S Kuramitsu et al.   CANCER GENE THERAPY